<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692832</url>
  </required_header>
  <id_info>
    <org_study_id>LH-VH</org_study_id>
    <nct_id>NCT03692832</nct_id>
  </id_info>
  <brief_title>Laparoscopic vs Vaginal Hysterectomy for Benign Gynaecological Disease</brief_title>
  <official_title>Laparoscopic Versus Vaginal Hysterectomy for Benign Gynaecological Disease in Ain Shams University Maternity Hospital: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare laparoscopic and vaginal hysterectomy in women with benign
      gynaecological disease in Ain Shams University Maternity Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative time</measure>
    <time_frame>duration of surgical procedure</time_frame>
    <description>Total operative time (minutes) for LH versus VH; from introduction of the first laparoscopy port or vaginal incision, till suturing the vaginal vault.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>intra-operative</time_frame>
    <description>Blood loss (mL): by measuring suctioned blood (subtracting irrigation volumes), Weighing sponges (weight difference of soaked and dry surgical gauzes, 1 g â‰ƒ 1 mL), or according to Gross (1983) formula (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>24 hours post-operative</time_frame>
    <description>Need for blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of successful vaginal opportunistic salpingectomy</measure>
    <time_frame>intra-operative</time_frame>
    <description>Proportion of patients with successful vaginal opportunistic salpingectomy or salpingo-oophorectomy compared to laparoscopic approach, and factors for non completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>intra-operative</time_frame>
    <description>Surgical complications: visceral or vascular injuries, vaginal cuff haematoma or dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain assessed using visual analogue scale for pain intensity</measure>
    <time_frame>first 24 hours post-operative</time_frame>
    <description>Post-operative pain: assessed using visual analogue scale for pain intensity at 2, 6 and 24 hours post-operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Febrile morbidity</measure>
    <time_frame>first 24 hours post-operative</time_frame>
    <description>Post-operative fever (temperature assessed in degrees Celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum markers for inflammation</measure>
    <time_frame>first 24 hours post-operative</time_frame>
    <description>Inflammatory response serum markers compared pre- and 24-h postoperatively (e.g. C-reactive protein or interleukin-6 according to availability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-stay</measure>
    <time_frame>1 week</time_frame>
    <description>Post-operative hospital-stay (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>1 week</time_frame>
    <description>Healthcare costs (EGP), including consumables, medications, and admission fees.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Benign Gynecological Disease</condition>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LH</intervention_name>
    <description>Laparoscopic hysterectomy (TLH or LHa)</description>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VH</intervention_name>
    <description>Vaginal hysterectomy</description>
    <arm_group_label>Group V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing hysterectomy for benign gynaecological disease (e.g., dysfunctional
             uterine bleeding, adenomyosis, fibroids).

        Exclusion Criteria: Women with:

          -  known tubo-ovarian pathology requiring primary laparotomy, e.g. large adnexal masses

          -  known neoplasia requiring pelvic lymphadenectomy

          -  pelvic organ prolapse requiring additional procedures, e.g., uterine procidentia
             (complete prolapse), enterocoele

          -  conditions interfering with laparoscopic surgery, e.g. cardio-pulmonary disease,
             obesity (BMI 30 kg/m2 or more)

          -  large uteri interfering with vaginal hysterectomy (size &gt;16 gestational weeks)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>September 30, 2018</last_update_submitted>
  <last_update_submitted_qc>September 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hamdy Bakry Alqenawy</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Diseases, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

